Heartflow falls 8% despite beating estimates on weak guidance

Heartflow reported Q4 adjusted EPS of -$0.12 vs consensus -$0.15 and revenue $49.1M, up 40% YoY; adjusted gross margin expanded to 79.9% from 75.3%. Full-year 2025 revenue was $176.0M (+40% YoY). Fiscal 2026 guidance calls for $218–$222M revenue (midpoint $220M, ~24–26% YoY growth) and adjusted gross margin of 80–81%, which appeared to disappoint investors and sent shares down ~7.6% after-hours. Operational highlights: U.S. installed base 1,465 accounts, U.S. Plaque installed base 489 accounts, and Aetna began coverage raising U.S. Plaque covered lives to ~75%.

Analysis

HeartFlow sits at an inflection where software-driven unit economics and payer coverage dynamics, not just device sales, determine value. As deployment scales, per-case cost falls and gross-margin leverage appears material, but that same path invites aggressive commoditization: large imaging OEMs and PACS vendors can replicate or bundle FFR-CT workflows into capital equipment and service contracts, putting long-term price pressure on standalone per-case pricing.

Near-term price action will be dominated by guidance-driven volatility and investor attention to next payer decisions; a small change in assumed uptake rates or a single large payer reversing course would move the stock meaningfully. Meaningful catalysts over months include additional national or large regional payer coverage decisions, high-visibility outcomes publications that change referral patterns, and any strategic partnership or tuck-in acquisition talks with incumbents — each would materially re-rate expectations or provide an exit path for private-equity/strategic buyers.

From a risk-management perspective, the company’s moat is clinical validation and workflow integration rather than proprietary hardware, which means the binary risks are asymmetric: slow, steady upside as adoption grows versus quick downside if reimbursement economics are contested. This creates option-friendly payoffs — buy-limited-duration upside exposure while avoiding full equity leverage; simultaneously monitor OEM product roadmaps and CMS-clearinghouse signals as the highest-probability regime switches over the next 3–18 months.

Key Decisions for Investors

• Long HTFL equity on meaningful weakness: accumulate on a 12–18% intraday gap-down from today’s close; size 1–2% of portfolio. Stop-loss at -30% from entry to limit downside from rapid reimbursement shocks. Rationale: captures upside if next-payer wins or sequential adoption beats lowered expectations; expect asymmetric 2–4x upside over 9–18 months if adoption and margins track current trajectory.
• Directional options (defined risk): buy a 9–12 month 15–25% OTM call debit spread (buy lower OTM call / sell higher OTM call) sized so max premium = 3–5% of position notional. This caps cost while providing ~3:1+ upside if shares rally beyond the short strike on positive payer or M&A news within a year. Exit or roll if no catalyst after 9 months; max loss = premium paid.
• Relative-value pair: long HTFL vs short a major imaging OEM (e.g., GE - GE) on equal notional, 6–12 month horizon. Thesis: software-first margin expansion and per-case growth should outpace legacy capital-equipment revenue if FFR-CT gains share; unwind if OEM announces bundled FFR-CT licensing with favorable economics or if HTFL issues multiple downward guidance revisions. Target relative return +20–30%, stop if spread narrows by 10% against position.